Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
Price trading | Ryguy008 | investorshub | 09/21/2023 12:45:35 PM |
$OKYO bears and bulls | mfayman | investorshub | 09/21/2023 12:14:10 PM |
short squeeze | Count Crypto | investorshub | 09/21/2023 11:41:39 AM |
are we finally gonna see some action | Count Crypto | investorshub | 09/21/2023 10:19:37 AM |
$OKYO short squeeze | mfayman | investorshub | 09/21/2023 10:18:42 AM |
$OKYO MomentumIts gaining up | Pisd | investorshub | 09/21/2023 10:02:06 AM |
$OKYO The gaining last trade up | mfayman | investorshub | 09/21/2023 8:58:11 AM |
Price now up | Count Crypto | investorshub | 09/21/2023 8:36:47 AM |
$OKYO got some short data | Sirpeter | investorshub | 09/21/2023 6:06:33 AM |
good read | mfayman | investorshub | 09/21/2023 5:38:57 AM |
$OKYO best news of the day | Boris the Spider | investorshub | 09/21/2023 5:08:41 AM |
$OKYO MomentumIts trading last trade up | Sirpeter | investorshub | 09/21/2023 4:34:48 AM |
$OKYO good read | Pisd | investorshub | 09/21/2023 4:32:31 AM |
MomentumIts trading last trade up | mfayman | investorshub | 09/21/2023 3:01:16 AM |
got some short data | mfayman | investorshub | 09/21/2023 2:54:26 AM |
Time for a bounce? | mfayman | investorshub | 09/21/2023 2:35:17 AM |
short squeeze article | Count Crypto | investorshub | 09/21/2023 2:18:01 AM |
$OKYO The gaining | AJ Freely | investorshub | 09/20/2023 11:14:39 PM |
$OKYO and the shorts continue | StocksNcash | investorshub | 09/20/2023 11:02:21 PM |
Time for this to show some returns | mfayman | investorshub | 09/20/2023 10:06:59 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...